1 February 2017 in JACC: Cardiovascular Interventions
1 April 2016 in The American Journal of Cardiology
1 May 2022 in Journal of Cardiovascular Computed Tomography
1 September 2015 in IJC Heart & Vasculature
We investigated the effect of chronic kidney disease (CKD) on morbidity and mortality following transcatheter aortic valve implantation (TAVI) including patients on haemodialysis, often excluded from randomised trials. We performed a retrospective post hoc analysis of all patients undergoing TAVI at our centre between 2008 and 2012. 118 consecutive patients underwent TAVI; 63 were considered as having (CKD) and 55 not having (No-CKD) significant pre-existing CKD, (defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2). Chronic haemodialysis patients (n = 4) were excluded from acute kidney injury (AKI) analysis. Following TAVI, in CKD and No-CKD patients respectively, AKI occurred in 23.7% and 14.5% (p = 0.455) and renal replacement therapy (RRT) was necessary in 8.5% and 3.6% (relative risk (RR) [95% CI] = 2.33 [0.47-11.5], p = 0.440); 30-day mortality rates were 6.3% and 1.8% (p = 0.370); and 1-year mortality rates were 17.5% and 18.2% (p = 0.919). Patients who developed AKI had a significantly increased risk of 30-day (12.5% vs. 1.1%, p = 0.029) mortality. We found the presence of diabetes (odds ratio (OR) [95% CI] = 4.58 [1.58-13.3], p = 0.005) and elevated baseline serum creatinine (OR [95% CI] = 1.02 [1.00-1.03], p = 0.026) to independently predict AKI to statistical significance by multivariate analysis. TAVI is a safe, acceptable treatment for patients with pre-existing CKD, however caution must be exercised, particularly in patients with pre-existing diabetes mellitus and elevated pre-operative serum creatinine levels as this confers a greater risk of AKI development, which is associated with increased short-term post-operative mortality.
15 September 2016 in European Heart Journal
This editorial refers to ‘Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials’, by G.C. Siontis et al. doi: 10.1093/eurheartj/ehw225. When transcatheter aortic valve implantation (TAVI) was first introduced, it was tested in clinical trials as a strategy against the gold standard treatment for symptomatic severe aortic stenosis, namely surgical aortic valve replacement (SAVR).1,2 Two first-generation valves (the Edwards Sapien Valve and Medtronic CoreValve) were studied in high surgical risk patients. In Cohort A of the PARTNER Trial, that TAVI should be non-inferior to surgery was seen as a major achievement for a first-generation valve.1 That TAVI might have superior outcomes to surgery, as suggested in the US PIVOTAL CoreValve Trial High Risk Cohort, was a surprise to many.2 Most commentators questioned ‘How did TAVI get so good?’ The US Pivotal Trial was the first TAVI trial to mandate rigorous computed tomography (CT) angiography pre-case planning, and changed practice as a result. It was carried out in the highest performing North American centres, with surgeons and interventionists of impeccable pedigree, and experienced proctors supervised many of the implants. Whilst it was clear that second-generation valves would be even better, the question remained if other trials would have similar findings. In this issue of the journal, Siontis and colleagues present a meta-analysis of four trials comparing TAVI with SAVR, comprising >3000 patients.3 They have included two trials, the NOTION Trial (the only completed TAVI vs. SAVR trial outside of North America), and the first TAVI Trial in a slightly less high risk patient population, PARTNER 2A in which patients were randomized to receive either the second-generation SAPIEN …
17 September 2018 in JACC